Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 2/2020

Open Access 01-04-2020 | Original Article

Preliminary Study on Selected Markers of Oxidative Stress, Inflammation and Angiogenesis in Patients with Bladder Cancer

Authors: Ewa Sawicka, Ewa Maria Kratz, Beata Szymańska, Anna Guzik, Artur Wesołowski, Paweł Kowal, Lilla Pawlik-Sobecka, Agnieszka Piwowar

Published in: Pathology & Oncology Research | Issue 2/2020

Login to get access

Abstract

In recent years, bladder cancer (BC) has been reported as one of the most commonly occurring cancers among older people, and its detection is still difficult. Therefore, there is a need to search for additional useful markers of disease. Some studies indicate the important roles of inflammation and oxidative stress (OS) in bladder tumour pathogenesis. The aim of this study was to examine the levels of selected markers of OS, inflammation and angiogenesis in blood plasma/serum samples derived from patients with BC, and a healthy control group. Moreover the degrees of change and strength of correlation between values of the analysed markers and tumour stage or grade were estimated. Concentrations of: malondialdehyde (MDA) and advanced oxidation protein products (AOPP), and total antioxidant status (TAS) divided into slow (TAS-s) and fast (TAS-f) antioxidants (spectrophotometric measurement), angiogenin (ANG) (immunoenzymatic method) and C-reactive protein (CRP) (immunoturbidimetric method) were determined in both the studied groups. The majority of values of the examined parameters were significantly higher among patients, while subfractions of TAS were significantly lower in comparison to the control group. Moreover, different values and different strengths of correlation between the examined parameters and cancer stage or grade were noticed. The most significant changes for CRP were observed in T2 and for MDA in G3, while the lowest TAS-f activity was revealed in G1 patients. Increased values of OS parameters, angiogenesis and inflammation markers, in combination with reduced TAS subfractions activity in BC are important in its pathogenesis and will be helpful in estimation of patients’ condition.
Literature
1.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374–1403PubMedCrossRef
2.
Didkowska J, Wojciechowska U, Sosnowski R In-depth analysis of epidemiological data, geographic differentiation and differentiation of morbidity and mortality due to urothelial diseases National Cancer Registry, Center for Oncology - Maria Skłodowska-Curie Institute. http://​onkologia.​org.​pl/​raporty/​. Access 15 Dec 2015
3.
4.
Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J (2004) Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem 266:37–56PubMedCrossRef
5.
Kong Q, Beel JA, Lillehei KO (2000) A threshold concept for cancer therapy. Med Hypotheses 5:529–535
6.
Brown NS, Bicknell R (2001) Hypoxia and oxidative stress in breast cancer: oxidative stress, its effects on the growth, metastatic potential, and response to therapy of breast cancer. Breast Cancer Res 3:323–327PubMedPubMedCentralCrossRef
7.
Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK (2008) Oxidative stress in inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res 68:1777–1785PubMedCrossRef
8.
Toyokuni S, Okamoto K, Yodoi J, Hiai H (1995) Persistent oxidative stress in cancer. FEBS Lett 358:1–3PubMedCrossRef
9.
Saed GM, Diamond MP, Fletcher NM (2017) Updates of the role of oxidative stress in the pathogenesis of ovarian cancer. Gynecol Oncol 145:595–602PubMedCrossRef
10.
Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB (2010) Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 49:1603–1616PubMedPubMedCentralCrossRef
11.
Sawicka E, Lisowska A, Kowal P, Długosz A (2015) The role of oxidative stress in bladder cancer. [Polish]. Postepy Hig Med Dosw 69:744–752CrossRef
12.
Kattoor JK, Pothineni NV, Palagiri D, Mehta JL (2017) Oxidative stress in atherosclerosis. Curr Atheroscler Rep 19:42–49PubMedCrossRef
13.
Tsikas D (2017) Assessment of lipid peroxidation by measuring malondialdehyde (MDA) and relatives in biological samples: analytical and biological challenges. Anal Biochem 524:13–30PubMedCrossRef
14.
Liu Q, Luo Q, Halim A, Song G (2017) Targeting lipid metabolism of cancer cells: a promising therapeutic strategy for cancer. Cancer Lett 401:39–45PubMedCrossRef
15.
Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C (2007) Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer 121:2381–2386PubMedCrossRef
16.
Witko-Sarsat V, Gausson V, Descamps-Latscha B (2003) Are advanced oxidation protein products potential uremic toxins? Kidney Int Suppl 84:11–14CrossRef
17.
Piwowar A (2010) Advanced oxidation products of proteins. Part I. Mechanism of formation, structure and properties. [Polish]. Pol Merkur Lekarski 28:166–169PubMed
18.
Ścibior-Bentkowska D, Czeczot H (2009) Cancer cells and oxidative stress. Adv Hyg Exp Med 63:58–72
19.
Yalçini O, Karataş F, Erulaş FA, Ozdemir E (2003) The levels of glutathione peroxidase, vitamin A, E, C and lipid peroxidation in patients with transitional cell carcinoma of the bladder. BJU Int 93:863–866CrossRef
20.
Mazdak H, Zia H (2012) Vitamin E reduces superficial bladder cancer recurrence: a randomized controlled trial. Int J Prev Med 3:110–115PubMedPubMedCentral
21.
22.
Shariat SF, Youseff RF, Gupta A, Chade DC, Karakiewicz PI, Isbarn H (2010) Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J Urol 183:1744–1750PubMedCrossRef
23.
Donmez G, Sullu Y, Baris S, Yildiz L, Aydin O, Karagoz F, Kandemir B (2009) Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas. Pathol Res Pract 205:854–857PubMedCrossRef
24.
Inoue K, Slaton JW, Kim SJ, Perrotte P, Eve BY, Bar-Eli M, Radinsky R, Dinney CP (2000) Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res 60:2290–2299PubMed
25.
Li S, Hu G (2010) Angiogenin-mediated rRNA transcription in cancer and neurodegeneration. Int J Biochem Mol Biol 1:26–35PubMedPubMedCentral
26.
Eissa S, Swellam M, Labib RA, El-Zayat T, El Ahmady O (2009) A panel of angiogenic factors for early bladder cancer detection: enzyme immunoassay and Western blot. J Urol 181:1353–1360PubMedCrossRef
27.
Shu J, Huang M, Tian Q, Shui Q, Zhou Y, Chen J (2015) Downregulation of angiogenin inhibits the growth and induces apoptosis in human bladder cancer cells through regulating AKT/mTOR signaling pathway. J Mol Histol 46:157–171PubMedCrossRef
28.
29.
Grivennikov SI, Karin M (2010) Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev 20:65–71PubMedCrossRef
30.
Gonda TA, Tu S, Wang TC (2009) Chronic inflammation, the tumor microenvironment and carcinogenesis. Cell Cycle 8:2005–2013PubMedCrossRef
31.
Eblin KE, Bredfeldt TG, Gandolfi AJ (2008) Immortalized human urothelial cells as a model of arsenic-induced bladder cancer. Toxicology 248:67–76PubMedCrossRef
32.
Meliker JR, Nriagu JO (2007) Arsenic in drinking water and bladder cancer: review of epidemiological evidence. Trace Metals and other Contaminants in the Environment 9:551–584CrossRef
33.
Romanenko A, Kakehashi A, Morimura K, Wanibuchi H, Wei M, Vozianov A, Fukushima S (2009) Urinary bladder carcinogenesis induced by chronic exposure to persistent low dose ionizing radiation after Chernobyl accident. Carcinogenesis 30:1821–1831PubMedCrossRef
34.
Schetter AJ, Heegaard NHH, Harris CC (2010) Inflammation and cancer: interweaving micro RNA, free radical, cytokine and p53 patchways. Carcinogenesis 31:37–49PubMedCrossRef
35.
36.
37.
Yoshioka T, Kawada K, Shimada T, Mori M (1979) Lipid peroxidation in maternal and cord blood and protective mechanism against activated-oxygen toxicity in the blood. Am J Obstet Gynecol 135:372–376PubMedCrossRef
38.
Re R, Pellegrini N, Proteggente A, Pannala A, Yang M, Rice-Evans C (1999) Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Radic Biol Med 26:1231–1237PubMedCrossRef
39.
Badjatia N, Satyam A, Singh P, Seth A, Sharma A (2010) Altered antioxidant status and lipid peroxidation in Indian patients with urothelial bladder carcinoma. Urol Oncol 28:360–367PubMedCrossRef
40.
Nechuta S, Lu W, Chen Z, Zheng Y, Gu K, Cai H, Zheng W, Shu XO (2011) Vitamin supplement use during breast cancer treatment and survival: a prospective cohort study. Cancer Epidemiol Biomark Prev 20:262–271CrossRef
41.
Gecit I, Aslan M, Gunes M, Pirincci N, Esen R, Demir H, Ceylan K (2012) Serum prolidase activity, oxidative stres and nitric oxide levels in patients with bladder cancer. J Cancer Res Clin Oncol 138:739–743PubMedPubMedCentralCrossRef
42.
Kosova F, Cetin B, Akinici M et al (2007) Advanced oxidation protein products, ferrous oxidation in xylenol orange and malondialdehyde levels in thyroid cancer. Ann Surg Oncol 14:2016–2020CrossRef
43.
Gakis G, Todenhӧfer T, Renninger M et al (2011) Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors the TNR-C score. BJU Int 108:1800–1805PubMedCrossRef
44.
Morka J, Drożdż J (2006) CRP - a high risk indicator and a new therapeutic target (CRP – wskaźnik podwyższonego ryzyka i nowy cel terapii). Forum Kardiol 11:27–31
45.
Saito K, Kihara K (2013) Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes. Int J Urol 20:161–171PubMedCrossRef
46.
Zhao H, Grossman B, George L et al (2005) Increased plasma levels of angiogenin and the risk of bladder carcinoma. Cancer 104:30–35PubMedCrossRef
47.
Urquidi V, Goodison S, Kim J, Chang M, Daib Y, Rosser CJ (2012) VEGF, CA9 and angiogenin as a urinary biomarker for bladder cancer detection. Urology 79:1185.e1–1185.e6CrossRef
48.
Metadata
Title
Preliminary Study on Selected Markers of Oxidative Stress, Inflammation and Angiogenesis in Patients with Bladder Cancer
Authors
Ewa Sawicka
Ewa Maria Kratz
Beata Szymańska
Anna Guzik
Artur Wesołowski
Paweł Kowal
Lilla Pawlik-Sobecka
Agnieszka Piwowar
Publication date
01-04-2020
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2020
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-019-00620-5

Other articles of this Issue 2/2020

Pathology & Oncology Research 2/2020 Go to the issue

Original Article

Molecular Network-Based Identification of Circular RNA-Associated ceRNA Network in Papillary Thyroid Cancer

Original Article

Acute and Late Toxicity after Moderate Hypofractionation with Simultaneous Integrated Boost (SIB) Radiation Therapy for Prostate Cancer. A Single Institution, Prospective Study

Letter to the Editor

Intravascular Occlusion by Leukemic Blast Cells Causing Multiplex Hand Necrosis in a Patient with Acute Myeloid Leukemia

Original Article

Identification of Pathogenic Genes and Transcription Factors in Osteosarcoma

Original Article

Evaluation of Alpha 1-Antitrypsin for the Early Diagnosis of Colorectal Cancer

Original Article

The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits